Group 1 - The core point of the article is that Wanbangde Pharmaceutical Holdings Group Co., Ltd. has received a patent for a new compound and its preparation method, which may enhance its competitive edge in the pharmaceutical industry [2] - Wanbangde's revenue composition for the year 2024 is as follows: 48.76% from pharmaceutical manufacturing, 32.21% from specialized equipment manufacturing and services, 15.41% from pharmaceutical distribution, and 3.62% from other industries [2]

证券代码：002082 证券简称：万邦德 公告编号：2025-047 万邦德医药控股集团股份有限公司 关于子公司获得发明专利的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 万邦德医药控股集团股份有限公司（以下简称"公司"）全资子公司万邦德 制药集团有限公司近日收到国家知识产权局的《发明专利证书》，具体情况如下： | 发明名称 | 一种二硫环肽化合物及其制备方法和应用 | | --- | --- | | 专利类型 | 发明专利 | | 专利号 | ZL202411896477.2 | | 授权公告日 | 2025.8.19 | | 专利权人 | 万邦德制药集团有限公司 | 本专利涉及一种具有特定二硫键结构的环肽化合物，以及其高效、可控的制 备方法和广泛的临床应用。通过分子内二硫键形成刚性环状结构，能精准调控人 体控制多种生理功能的不同受体，其作为黑皮质素受体的高选择性配体，可在外 周或神经系统疾病、炎症、自身免疫性疾病、代谢性疾病、癌症、呼吸系统疾病、 心血管疾病、生殖系统疾病等领域治疗提供新的候选药物分子。同时，独特的结 构可提升药物的靶向性、稳定性、 ...

| 代码 | 名称 | | 涨幅% ↓ | 总市值 | 年初至今涨幅% | | --- | --- | --- | --- | --- | --- | | 300147 | ST香雪 | 1 | 16.47 | 58.92亿 | -8.80 | | 300199 | 翰宇药业 | 1 | 12.05 | 258亿 | 126.53 | | 002082 | 万邦德 | | 10.01 | 49.06亿 | 24.73 | | 600535 | 天士力 | 1 | 7.73 | 260亿 | 22.17 | | 688091 | 上海谊众 | નાર | 6.94 | 169亿 | 104.93 | | 688319 | 欧林生物 | | 5.63 | 103亿 | 139.06 | | 688621 | 阳光诺和 | 一座 | 5.22 | 90.33亿 | 114.56 | | 430047 | 诺思兰德 | -06 | 4.62 | 67.06 Z | 112.06 | | 300683 | 海特生物 | નહ | 4.08 | 75.41亿 | 143.08 | | 688189 | 南新制药 | 来 ...

Core Points - The Shanghai Composite Index closed at 3638.40 points with a change of 0.12% and a total trading volume of 1,206.179 billion yuan [1] - Eight A-shares experienced a crossover where the 5-day moving average fell below the 10-day moving average, indicating potential bearish trends [1] Group 1: Stock Performance - Stock "信立泰" (Code: 002294) decreased by 1.86% with a 5-day moving average of 49.37 yuan and a 10-day moving average of 49.62 yuan, showing a distance of -0.49% [1] - Stock "万邦德" (Code: 002082) decreased by 1.36% with a 5-day moving average of 7.48 yuan and a 10-day moving average of 7.52 yuan, also showing a distance of -0.49% [1] - Stock "毕得医药" (Code: 688073) decreased by 2.96% with a 5-day moving average of 59.09 yuan and a 10-day moving average of 59.27 yuan, indicating a distance of -0.30% [1] Group 2: Additional Stocks with Moving Average Crossovers - Stock "吉贝尔" (Code: 688566) decreased by 3.58% with a 5-day moving average of 33.90 yuan and a 10-day moving average of 33.97 yuan, showing a distance of -0.20% [1] - Stock "诺诚健华" (Code: 688428) decreased by 6.03% with a 5-day moving average of 30.02 yuan and a 10-day moving average of 30.07 yuan, indicating a distance of -0.18% [1] - Stock "丽人丽妆" (Code: 605136) increased by 0.81% with a 5-day moving average of 9.82 yuan and a 10-day moving average of 9.84 yuan, showing a distance of -0.15% [1]

Core Viewpoint - The A-share market is experiencing a slight decline, with the Shanghai Composite Index down by 0.28% and a total trading volume of 878.86 billion yuan as of 10:30 AM [1] Group 1: Market Performance - The Shanghai Composite Index is at 3623.70 points, reflecting a decrease of 0.28% [1] - The total trading volume in the A-share market is reported at 878.86 billion yuan [1] Group 2: Moving Averages Analysis - Seven A-shares have seen their 5-day moving averages cross below their 10-day moving averages, indicating potential bearish trends [1] - Notable stocks with significant distance between their 5-day and 10-day moving averages include: - Xintai (002294) with a distance of -0.51% - Wanbangde (002082) with a distance of -0.45% - Haixiang Pharmaceutical (002099) with a distance of -0.24% [1] Group 3: Individual Stock Performance - Xintai (002294) is down by 2.07% with a latest price of 47.79 yuan, which is 3.66% below its 10-day moving average [1] - Wanbangde (002082) has decreased by 0.95%, trading at 7.30 yuan, 2.93% below its 10-day moving average [1] - Haixiang Pharmaceutical (002099) is down by 0.33%, with a latest price of 6.08 yuan, 1.95% below its 10-day moving average [1] - Other stocks such as Bidai Pharmaceutical (688073) and Kewah (002335) also show declines in their respective prices and moving averages [1]

Core Viewpoint - Wanbangde Pharmaceutical Holdings Group Co., Ltd. has launched a national conference for the Phase II/III clinical trial of its new drug Huperzine A controlled-release tablets for Alzheimer's disease, emphasizing the importance of local research and collaboration among experts [1][2]. Group 1: Clinical Trial Launch - The national launch conference for the Phase II/III clinical trial of Huperzine A controlled-release tablets was held in Beijing [1]. - Experts gathered to discuss the significance of the trial and to collaborate on high-quality development of the drug [1]. Group 2: Research and Development Insights - Professor Jia Jianping highlighted the trial's importance and encouraged local researchers to take pride in their work [1]. - Zhao Guanjia, the director of Wanbangde's research institute, discussed the company's focus on Huperzine A and its extensive groundwork in related research [1]. Group 3: Safety and Efficacy - Researcher Gan Yong shared the development history of Huperzine A controlled-release tablets, noting the urgent need for effective and well-tolerated drugs for Alzheimer's patients [2]. - Director Yan Feng provided insights into the safety profile of the drug, indicating that preliminary data supports its good safety and pharmacological characteristics [2]. Group 4: Training and Standardization - The conference included comprehensive training on the research protocol, operational processes, and key execution points to ensure a unified understanding among all researchers [2].

New Stock Issuance - New stock issued by Dingjia Precision at a price of 11.16 on July 22, 2025[1] - ST Kelly's tender offer period is from July 17 to August 15, 2025[1] - ST Zitian and other companies have also announced new stock issuances[1] Market Alerts - Significant abnormal fluctuations reported for several stocks including Guangshengtang and Huayin Power[1] - Multiple companies have disclosed announcements regarding stock performance and market activities[1] - The report includes links to detailed announcements for various stocks, indicating ongoing market monitoring[1]

New Stock Issuance - The new stock issued by Hanguo Group is priced at 15.43 RMB per share[1] - The subscription period for the tender offer of ST Kelly is from July 17, 2025, to August 15, 2025[1] Abnormal Fluctuations - Several stocks, including ST Zitian and Guangshengtang, have reported severe abnormal fluctuations[2] - The announcement links for stocks experiencing abnormal fluctuations are provided for investor reference[2] Market Updates - A total of 30 stocks have been listed for trading updates, with various announcements made between July 15 and July 21, 2025[1] - The report includes links to detailed announcements for each stock, ensuring transparency and accessibility for investors[1]

Market Performance - A-shares steadily advanced this week, with the ChiNext Index reaching a new high for the year and the Shenzhen Component Index hitting a four-month high, approaching its highest point of the year [1] - Weekly trading volume increased to 7.73 trillion yuan, marking the largest weekly trading volume in three months [1] Fund Inflows - Leverage funds actively entered the market, with most industries under the Shenwan first-level industry classification seeing net buying, particularly the computer industry with over 4.4 billion yuan and the electronics industry with over 3 billion yuan [2] - The electronic, biopharmaceutical, and automotive sectors each received over 20 billion yuan in net inflows, while the non-bank financial sector saw a net outflow of over 8.3 billion yuan [2] Rare Earth Demand - The rare earth sector performed strongly, with the rare earth permanent magnet index reaching a three-and-a-half-year high [3] - Demand for rare earths is expected to grow rapidly due to advancements in humanoid robots and electric vehicles, with estimates suggesting a demand of at least 70,000 tons of neodymium-iron-boron by 2025 [3] Energy Metals - The energy metals sector, including lithium and cobalt, reached a two-year high, with lithium carbonate futures breaking 70,000 yuan/ton, marking a 20% increase from recent lows [4] - Short-term lithium salt supply may decline due to reduced exports from Chile and domestic production halts, leading to a potential price stabilization [4] Biopharmaceutical Sector - The biopharmaceutical sector saw significant gains, with the innovative drug index hitting record highs multiple times this week [6] - Notable stocks in the sector, such as Lianhuan Pharmaceutical and Aosaikang, experienced consecutive trading halts, with some stocks showing year-to-date gains exceeding 200% [6][7] Earnings Forecasts - Several pharmaceutical companies have recently forecasted substantial profit increases for the first half of 2025, with estimates suggesting net profit growth exceeding 19 times for some firms [7]

Group 1 - The company's stock experienced an abnormal trading fluctuation, with a cumulative closing price increase exceeding 20% over three consecutive trading days (July 14, 2025, July 15, 2025, and July 16, 2025) [1] - The company conducted an internal review and confirmed that there were no undisclosed significant matters affecting the stock price, and the operational situation remains normal [2][3] - The company has not identified any recent media reports that could have significantly impacted the stock trading price [2] Group 2 - The company confirmed that there are no undisclosed matters that should be disclosed according to the Shenzhen Stock Exchange regulations [3] - The company announced a half-year performance forecast on July 15, 2025, with no need for corrections [4] - The company’s controlling shareholder intends to transfer 60 million shares, representing 9.8089% of the total share capital, which is subject to compliance review and transfer procedures [4] Group 3 - The company emphasizes the importance of rational investment and awareness of market risks, particularly given the recent volatility in stock prices [4][5]